Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy
Purpose To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa). Methods A total of 86 patients with localized prostate cancer were treated with open radic...
Gespeichert in:
| Veröffentlicht in: | Tumori 2017-03, Vol.103 (2), p.204-208 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 208 |
|---|---|
| container_issue | 2 |
| container_start_page | 204 |
| container_title | Tumori |
| container_volume | 103 |
| creator | Arslan, Burak Onuk, Özkan Hazar, İsmet Aydın, Muammer Çilesiz, Nusret Can Eroglu, Ali Nuhoglu, Barış |
| description | Purpose
To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa).
Methods
A total of 86 patients with localized prostate cancer were treated with open radical prostatectomy (RP). The control group included 80 patients who were referred to the urology outpatient clinic with normal rectal examination and prostate-specific antigen (PSA) levels. The patients’ characteristics, baseline PSA value, and serum endocan levels were recorded. The patients were followed up with the measurement of PSA concentration every 3 months during the first year, thereafter every 6 months until 5 years, then yearly after surgery. The primary endpoint of follow-up was the time of biochemical recurrence.
Results
The median serum endocan levels were 3.14 ng/mL in the RP group and 2.98 ng/mL in the control group (p = 0.122). A total of 86 patients who underwent RP for PCa were divided into 2 groups based on a cutoff serum endocan level of 1.8 ng/mL. The distribution of Gleason score and biochemical failure rate were significantly higher in patients with serum endocan ≥1.8 ng/mL (p = 0.031 and p = 0.047). The biochemical recurrence-free time for endocan ≥1.8 ng/mL and |
| doi_str_mv | 10.5301/tj.5000535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826735465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5301_tj.5000535</sage_id><sourcerecordid>1826735465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-3c4aba4eb3dbbe510d5f949a1aa943d78ab52e21b386ea8c8bfdc0519d95932f3</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi0EotvChR-AfANVSvFHnMTcyqp8SCuBysc1GtuTrVeJvbUdUH8O_5TAbnviNId55pkZvYS84OxCScbflN2FYowpqR6RlWCyq4QS-jFZMclY1WnenJDTnHeM1Uw0zVNyItq6ZQ1rV-T3lxS3IebiLf0B44w0DvQquGghUB_o0s4FCtI1BIvpLV2PPngb91Bu4hi3y9hlztF6KD4GarD8Qgz0K6Z5evBs8CeOmUJw9J2P9gYnb2Gk12jnlHDxUhgKJnoN7l_jfqktcbp7Rp4MMGZ8fqxn5Pv7q2_rj9Xm84dP68tNZSXXpZK2BgM1GumMQcWZU4OuNXAAXUvXdmCUQMGN7BqEznZmcJYprp1WWopBnpHXB-8-xdsZc-knny2OIwSMc-55J5pWqrpRC3p-QO1yaE449PvkJ0h3PWf930j6suuPkSzwy6N3NhO6B_Q-gwV4dQAybLHfxTmF5c__qf4AxTmW8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826735465</pqid></control><display><type>article</type><title>Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Arslan, Burak ; Onuk, Özkan ; Hazar, İsmet ; Aydın, Muammer ; Çilesiz, Nusret Can ; Eroglu, Ali ; Nuhoglu, Barış</creator><creatorcontrib>Arslan, Burak ; Onuk, Özkan ; Hazar, İsmet ; Aydın, Muammer ; Çilesiz, Nusret Can ; Eroglu, Ali ; Nuhoglu, Barış</creatorcontrib><description>Purpose
To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa).
Methods
A total of 86 patients with localized prostate cancer were treated with open radical prostatectomy (RP). The control group included 80 patients who were referred to the urology outpatient clinic with normal rectal examination and prostate-specific antigen (PSA) levels. The patients’ characteristics, baseline PSA value, and serum endocan levels were recorded. The patients were followed up with the measurement of PSA concentration every 3 months during the first year, thereafter every 6 months until 5 years, then yearly after surgery. The primary endpoint of follow-up was the time of biochemical recurrence.
Results
The median serum endocan levels were 3.14 ng/mL in the RP group and 2.98 ng/mL in the control group (p = 0.122). A total of 86 patients who underwent RP for PCa were divided into 2 groups based on a cutoff serum endocan level of 1.8 ng/mL. The distribution of Gleason score and biochemical failure rate were significantly higher in patients with serum endocan ≥1.8 ng/mL (p = 0.031 and p = 0.047). The biochemical recurrence-free time for endocan ≥1.8 ng/mL and <1.8 ng/mL were 38 and 56 months, respectively (p = 0.041). Spearman correlation analysis showed a linear relationship between endocan expression and Gleason score (p = 0.025, p = 0.511). Multivariate analysis revealed that elevated serum endocan level (≥1.8 ng/mL) was a significant predictor of biochemical progression-free survival (hazard ratio 2.44; 95% confidence interval 1.78-3.23; p = 0.001).
Conclusions
The current study indicates that endocan has a close relationship with tumor recurrence in PCa.</description><identifier>ISSN: 0300-8916</identifier><identifier>EISSN: 2038-2529</identifier><identifier>DOI: 10.5301/tj.5000535</identifier><identifier>PMID: 27470607</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Biomarkers, Tumor - blood ; Case-Control Studies ; Disease-Free Survival ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Grading - methods ; Neoplasm Proteins - blood ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Prognosis ; Proportional Hazards Models ; Prostate-Specific Antigen - blood ; Prostatectomy - methods ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Proteoglycans - blood</subject><ispartof>Tumori, 2017-03, Vol.103 (2), p.204-208</ispartof><rights>2017 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-3c4aba4eb3dbbe510d5f949a1aa943d78ab52e21b386ea8c8bfdc0519d95932f3</citedby><cites>FETCH-LOGICAL-c319t-3c4aba4eb3dbbe510d5f949a1aa943d78ab52e21b386ea8c8bfdc0519d95932f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.5301/tj.5000535$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.5301/tj.5000535$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27470607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arslan, Burak</creatorcontrib><creatorcontrib>Onuk, Özkan</creatorcontrib><creatorcontrib>Hazar, İsmet</creatorcontrib><creatorcontrib>Aydın, Muammer</creatorcontrib><creatorcontrib>Çilesiz, Nusret Can</creatorcontrib><creatorcontrib>Eroglu, Ali</creatorcontrib><creatorcontrib>Nuhoglu, Barış</creatorcontrib><title>Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy</title><title>Tumori</title><addtitle>Tumori</addtitle><description>Purpose
To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa).
Methods
A total of 86 patients with localized prostate cancer were treated with open radical prostatectomy (RP). The control group included 80 patients who were referred to the urology outpatient clinic with normal rectal examination and prostate-specific antigen (PSA) levels. The patients’ characteristics, baseline PSA value, and serum endocan levels were recorded. The patients were followed up with the measurement of PSA concentration every 3 months during the first year, thereafter every 6 months until 5 years, then yearly after surgery. The primary endpoint of follow-up was the time of biochemical recurrence.
Results
The median serum endocan levels were 3.14 ng/mL in the RP group and 2.98 ng/mL in the control group (p = 0.122). A total of 86 patients who underwent RP for PCa were divided into 2 groups based on a cutoff serum endocan level of 1.8 ng/mL. The distribution of Gleason score and biochemical failure rate were significantly higher in patients with serum endocan ≥1.8 ng/mL (p = 0.031 and p = 0.047). The biochemical recurrence-free time for endocan ≥1.8 ng/mL and <1.8 ng/mL were 38 and 56 months, respectively (p = 0.041). Spearman correlation analysis showed a linear relationship between endocan expression and Gleason score (p = 0.025, p = 0.511). Multivariate analysis revealed that elevated serum endocan level (≥1.8 ng/mL) was a significant predictor of biochemical progression-free survival (hazard ratio 2.44; 95% confidence interval 1.78-3.23; p = 0.001).
Conclusions
The current study indicates that endocan has a close relationship with tumor recurrence in PCa.</description><subject>Biomarkers, Tumor - blood</subject><subject>Case-Control Studies</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Grading - methods</subject><subject>Neoplasm Proteins - blood</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Proteoglycans - blood</subject><issn>0300-8916</issn><issn>2038-2529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1v1DAQhi0EotvChR-AfANVSvFHnMTcyqp8SCuBysc1GtuTrVeJvbUdUH8O_5TAbnviNId55pkZvYS84OxCScbflN2FYowpqR6RlWCyq4QS-jFZMclY1WnenJDTnHeM1Uw0zVNyItq6ZQ1rV-T3lxS3IebiLf0B44w0DvQquGghUB_o0s4FCtI1BIvpLV2PPngb91Bu4hi3y9hlztF6KD4GarD8Qgz0K6Z5evBs8CeOmUJw9J2P9gYnb2Gk12jnlHDxUhgKJnoN7l_jfqktcbp7Rp4MMGZ8fqxn5Pv7q2_rj9Xm84dP68tNZSXXpZK2BgM1GumMQcWZU4OuNXAAXUvXdmCUQMGN7BqEznZmcJYprp1WWopBnpHXB-8-xdsZc-knny2OIwSMc-55J5pWqrpRC3p-QO1yaE449PvkJ0h3PWf930j6suuPkSzwy6N3NhO6B_Q-gwV4dQAybLHfxTmF5c__qf4AxTmW8A</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Arslan, Burak</creator><creator>Onuk, Özkan</creator><creator>Hazar, İsmet</creator><creator>Aydın, Muammer</creator><creator>Çilesiz, Nusret Can</creator><creator>Eroglu, Ali</creator><creator>Nuhoglu, Barış</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy</title><author>Arslan, Burak ; Onuk, Özkan ; Hazar, İsmet ; Aydın, Muammer ; Çilesiz, Nusret Can ; Eroglu, Ali ; Nuhoglu, Barış</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-3c4aba4eb3dbbe510d5f949a1aa943d78ab52e21b386ea8c8bfdc0519d95932f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Biomarkers, Tumor - blood</topic><topic>Case-Control Studies</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Grading - methods</topic><topic>Neoplasm Proteins - blood</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Proteoglycans - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arslan, Burak</creatorcontrib><creatorcontrib>Onuk, Özkan</creatorcontrib><creatorcontrib>Hazar, İsmet</creatorcontrib><creatorcontrib>Aydın, Muammer</creatorcontrib><creatorcontrib>Çilesiz, Nusret Can</creatorcontrib><creatorcontrib>Eroglu, Ali</creatorcontrib><creatorcontrib>Nuhoglu, Barış</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Tumori</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arslan, Burak</au><au>Onuk, Özkan</au><au>Hazar, İsmet</au><au>Aydın, Muammer</au><au>Çilesiz, Nusret Can</au><au>Eroglu, Ali</au><au>Nuhoglu, Barış</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy</atitle><jtitle>Tumori</jtitle><addtitle>Tumori</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>103</volume><issue>2</issue><spage>204</spage><epage>208</epage><pages>204-208</pages><issn>0300-8916</issn><eissn>2038-2529</eissn><abstract>Purpose
To assess the diagnostic capability of serum endocan level in association with clinicopathologic features and its impact on biochemical progression-free survival in patients with prostate cancer (PCa).
Methods
A total of 86 patients with localized prostate cancer were treated with open radical prostatectomy (RP). The control group included 80 patients who were referred to the urology outpatient clinic with normal rectal examination and prostate-specific antigen (PSA) levels. The patients’ characteristics, baseline PSA value, and serum endocan levels were recorded. The patients were followed up with the measurement of PSA concentration every 3 months during the first year, thereafter every 6 months until 5 years, then yearly after surgery. The primary endpoint of follow-up was the time of biochemical recurrence.
Results
The median serum endocan levels were 3.14 ng/mL in the RP group and 2.98 ng/mL in the control group (p = 0.122). A total of 86 patients who underwent RP for PCa were divided into 2 groups based on a cutoff serum endocan level of 1.8 ng/mL. The distribution of Gleason score and biochemical failure rate were significantly higher in patients with serum endocan ≥1.8 ng/mL (p = 0.031 and p = 0.047). The biochemical recurrence-free time for endocan ≥1.8 ng/mL and <1.8 ng/mL were 38 and 56 months, respectively (p = 0.041). Spearman correlation analysis showed a linear relationship between endocan expression and Gleason score (p = 0.025, p = 0.511). Multivariate analysis revealed that elevated serum endocan level (≥1.8 ng/mL) was a significant predictor of biochemical progression-free survival (hazard ratio 2.44; 95% confidence interval 1.78-3.23; p = 0.001).
Conclusions
The current study indicates that endocan has a close relationship with tumor recurrence in PCa.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27470607</pmid><doi>10.5301/tj.5000535</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8916 |
| ispartof | Tumori, 2017-03, Vol.103 (2), p.204-208 |
| issn | 0300-8916 2038-2529 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826735465 |
| source | MEDLINE; SAGE Complete |
| subjects | Biomarkers, Tumor - blood Case-Control Studies Disease-Free Survival Humans Male Middle Aged Multivariate Analysis Neoplasm Grading - methods Neoplasm Proteins - blood Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery Prognosis Proportional Hazards Models Prostate-Specific Antigen - blood Prostatectomy - methods Prostatic Neoplasms - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Proteoglycans - blood |
| title | Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A26%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Value%20of%20Endocan%20in%20Prostate%20Cancer:%20Clinicopathologic%20Association%20between%20Serum%20Endocan%20Levels%20and%20Biochemical%20Recurrence%20after%20Radical%20Prostatectomy&rft.jtitle=Tumori&rft.au=Arslan,%20Burak&rft.date=2017-03-01&rft.volume=103&rft.issue=2&rft.spage=204&rft.epage=208&rft.pages=204-208&rft.issn=0300-8916&rft.eissn=2038-2529&rft_id=info:doi/10.5301/tj.5000535&rft_dat=%3Cproquest_cross%3E1826735465%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826735465&rft_id=info:pmid/27470607&rft_sage_id=10.5301_tj.5000535&rfr_iscdi=true |